Snow Software Introduces New Global Partner Program to Drive Exponential Growth in Channel Ecosystem
1.2.2023 17:00:00 EET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today announced a new global partner program designed to enable partners to support customers as they face complex market challenges around managing cost and mitigating risk, while delivering value more efficiently and effectively with Snow. The new program aims to drive exponential growth in the Snow channel ecosystem, creating new opportunities for partners to tap into an estimated and growing $11.5 billion Technology Intelligence market.
Developed in collaboration with its current channel ecosystem, the new Snow partner program includes better support for multiple business models of partners, encouraging the creation of value-added services and driving tangible customer success by leveraging Snow technology. The program includes more partner incentives and rewards than the current program, while streamlining collaboration with Snow to better deliver value to shared customers.
“Today’s economic climate demands more from every organization’s IT technology environment, which means that our partners have a greater responsibility to provide visibility, governance and optimization services for their customers,” said Vinod Chumber, Vice President of Ecosystem Sales at Snow. “In order to ensure our partners can deliver excellent outcomes, it was essential to create a new program that better enabled them with the right resources, education and solutions to succeed. As a partner-centric organization, we believe that our new program combined with our Snow Atlas platform is a powerful combination to address the turbulent market customers and partners face today. The new program is just the beginning as we continue to invest in our partners and create a rich ecosystem enabled to take advantage of the vision for Technology Intelligence.”
Creating transparency with the market, the partner portal will feature real-time dashboards featuring each partner’s strong record of success and specializations to arm customers with insight on the best partners suited to their needs. The new framework will remove channel conflicts, empowering partners to build new, value-add services and work closely with the Snow wider teams to drive customer success. Additional new program benefits include:
- Sales rewards and points system to recognize the investment that individuals within the partner organization are making;
- Self-service capabilities to create new operational efficiencies within the partner portal;
- Business development funds to market and promote partner sales offerings built on top of Snow technology;
- Shadowing programs to drive customer success and adoption of Snow best practices and certification opportunities;
- Free access to Snow e-learning to empower partners with the latest knowledge on the Snow product and solution portfolio;
- Snow Champion Program to recognize and reward individuals for their contribution to the Snow community; and
- Ongoing recognition and rewards opportunities including annual partner awards to celebrate the success, rewards for joint customer success stories and more.
“Our clients need powerful solutions and tools to deliver tangible business value, reduce overall IT costs and mitigate risks,” said Shadi Khoshab, Global Director, ITAM & Software Sourcing Services at SoftwareOne. “By enhancing and innovating its partner program, Snow is demonstrating its commitment to our strategic relationship and helping to drive our joint business forward, empowering our clients with invaluable, actionable insights that underpins successful digital transformation.”
In addition to the overall program, Snow is committed to releasing ongoing product capabilities specifically aimed at enabling its partner community. Most recently, Snow introduced two new Snow Atlas capabilities for partners to better support their customers with improved collaboration features. Customers can now give partners direct access to their Snow Atlas platform, allowing partners to manage customer environments in the cloud. In addition, partners can now create agent packages with a self-service tool in Snow Atlas without engaging Snow Support, making the end-to-end delivery more efficient.
The new Snow partner program will be available for all partners later this year. For more information about the Snow partner ecosystem or to become a Snow partner, please visit: https://www.snowsoftware.com/global-partner-program/.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005359/en/
Contact information
Rachel Austin
Snow Software
press@snowsoftware.com
Taylor Champlin
PAN Communications
snow@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
